2023-503892-83-00RecruitingPhase 1
First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers
Vivet Therapeutics1 site in 1 country35 target enrollmentStarted: September 28, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 35
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Info Vivet
Scientific
Vivet Therapeutics
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adultsSexual Transmitted Infection (STI)2024-519328-26-01Debiopharm International S.A.88
Recruiting
Phase 1
A First-in-human Study to Evaluate the Safety and Anticancer Effect of Several Doses of TH9619 in Patients with Advanced Cancer (ODIN).Solid tumors (including Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), squamous cell carcinoma of the head and neck (HNSCC), and Gastric Cancer (GC))2024-519639-40-00One-carbon Therapeutics AB33
Recruiting
Phase 1
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancerProgressive metastatic solid cancer after failure of established treatment options2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
Recruiting
Phase 1
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid TumorsAdvanced solid tumors including non-small cell lung cancer (NSCLC), mesothelioma, pancreatic adenocarcinoma, head and neck carcinoma, ovarian cancer, cervical carcinoma, uterine carcinoma and breast cancer.2022-502867-39-00Amgen Inc.58
Recruiting
Phase 1
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancersAdvanced solid tumors (cutaneous melanoma, mucosal melanoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, or basal cell carcinoma)2025-522402-21-00Kupando GmbH21